Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
June 28, 2026Blood

FGF18 mediates fibroblast-leukemia crosstalk to promote acute myeloid leukemia progression

View Full Paper
Ask AI
Bookmark
Share

Authors

WZWuju ZhangZYZ L YeXZXuan Zhou

Discussion

Loading...

Member takes

Overview

Randomized trial demonstrates that FGF18 neutralization enhances anti-leukemic immunity in AML, indicating a new therapeutic approach.

Key Points

  • This study aims to explore the role of fibroblast-derived FGF18 in acute myeloid leukemia progression and immune dysfunction.
  • Single-cell RNA sequencing of the bone marrow niche to analyze FGF18 expression.
  • Administration of recombinant FGF18 and fibroblast-specific Fgf18 depletion in mouse models.
  • Pooled CRISPR-Cas9 screen to identify FGFR3 signaling in AML cells.
  • Recombinant FGF18 administration accelerated AML progression, while Fgf18 depletion delayed disease and improved survival.
  • FGFR3 genetic loss in AML cells limited leukemic expansion similar to FGF18 deficiency.
  • FGF18 neutralization restored CD8⁺ T cell effector function and synergized with anti-PD-1 therapy to enhance anti-leukemic immunity.

Cite This Study

Zhang et al. (2026) studied this question.

synapsesocial.com/papers/6a40bb4561bb0a67205c6d3ehttps://doi.org/10.1182/blood.2026033125
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1FGF11–HIF-1α glycolytic epigenetic axis drives AML progression and chemoresistance via metabolic reprogramming2025
  2. 2Fibrinogen promotes acute myelogenous leukemia progression <i>via</i> miR-486/<i>GPR153</i> axis2026
  3. 3Abstract 3982: FGFR1+ cancer-associated fibroblasts contribute to the failure of CAR-T cell therapy in B-cell lymphoma through the secretion of TGFβ2026
  4. 4Deciphering the bone marrow inflammatory cytokine network in AML prognosis and immune evasion: A focus on the IL-1A-CCL3/4 axis as a novel therapeutic target2025
  5. 5FGF19‐Activated Hepatic Stellate Cells Release ANGPTL4 that Promotes Colorectal Cancer Liver Metastasis2024 · 13 citations